Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
Biomarkers in Blood 2016
share announcement

Biomarkers in Blood 2016

A special issue of Diagnostics (ISSN 2075-4418).

Deadline for manuscript submissions: closed (31 July 2016) | Viewed by 32559

Special Issue Editor

Dr. Ludmilla A. Morozova-Roche

E-Mail Website
Guest Editor
Department of Medical Biochemistry and Biophsyics, Umeå Univeristy, SE 90187 Umeå, Sweden
Interests: biodiagnostics; amyloid; protein misfolding; neuroinflammation; cellular toxicity; neurodegenerative diseases; blood serum; CSF; bioimaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The issue "Biomarkers in Blood" will be focused on the diagnostics of plethora of pathologies, including such widely spread ailments as cancer, neurodegenerative Alzheimer’s, Parkinson’s and other diseases as well as other pathological conditions, by using biomarkers in the blood. Due to a growing elderly population, these diseases are on the rise in the modern society and combatting them is a global issue. The early or even pre-clinical diagnostics of pathological conditions at the stage when the clinical symptoms are not obvious would be of significant therapeutic value and would enable to administer protective or preventive treatments at an earlier stage. The molecular constitution of blood can be highly representative of the physiological state of an individual. Patient blood serum analyses are potentially minimally invasive and cheap means of both early disease detection and the convenient monitoring of disease response to therapeutic intervention. These approaches are tightly aligned with the concept of personalised healthcare. Over last few years, a range of new robust diagnostic assays underpinning the presymptomatic detection of pathological conditions were established, as well as a range of new biomarkers associated with the disease pathology were discovered. Biodiagnostics is a rapidly expanding field, yet many problems need to be solved. Experience shows that candidate biomarkers may fail to demonstrate their clinical utility, which can be because they are genuinely not relevant to the disease, or their validation has been limited to a subset of patients to whom they are relevant, or the technical limitations of the detection methods.

The present Special Issue aims at bringing a collection of research and reviewer articles together to summarize a state of the art, problems and future directions in the biomarker and biodiagnostics field based on the blood analysis. Your contributions are very welcome!

Yours faithfully,

Prof. Dr. Ludmilla Morozova-Roche
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarker
  • biosensor assay
  • diagnostics
  • blood analysis
  • presymptomatic detection
  • disease monitoring
  • cancer
  • neurodegenerative diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

2030 KiB  
Review
Fatty Acids in Membranes as Homeostatic, Metabolic and Nutritional Biomarkers: Recent Advancements in Analytics and Diagnostics
by Carla Ferreri, Annalisa Masi, Anna Sansone, Giorgia Giacometti, Anna Vita Larocca, Georgia Menounou, Roberta Scanferlato, Silvia Tortorella, Domenico Rota, Marco Conti, Simone Deplano, Maria Louka, Anna Rosaria Maranini, Arianna Salati, Valentina Sunda and Chryssostomos Chatgilialoglu
Diagnostics 2017, 7(1), 1; https://doi.org/10.3390/diagnostics7010001 - 22 Dec 2016
Cited by 87 | Viewed by 10552
Abstract
Fatty acids, as structural components of membranes and inflammation/anti-inflammatory mediators, have well-known protective and regulatory effects. They are studied as biomarkers of pathological conditions, as well as saturated and unsaturated hydrophobic moieties in membrane phospholipids that contribute to homeostasis and physiological functions. Lifestyle, [...] Read more.
Fatty acids, as structural components of membranes and inflammation/anti-inflammatory mediators, have well-known protective and regulatory effects. They are studied as biomarkers of pathological conditions, as well as saturated and unsaturated hydrophobic moieties in membrane phospholipids that contribute to homeostasis and physiological functions. Lifestyle, nutrition, metabolism and stress—with an excess of radical and oxidative processes—cause fatty acid changes that are examined in the human body using blood lipids. Fatty acid-based membrane lipidomics represents a powerful diagnostic tool for assessing the quantity and quality of fatty acid constituents and also for the follow-up of the membrane fatty acid remodeling that is associated with different physiological and pathological conditions. This review focuses on fatty acid biomarkers with two examples of recent lipidomic research and health applications: (i) monounsaturated fatty acids and the analytical challenge offered by hexadecenoic fatty acids (C16:1); and (ii) the cohort of 10 fatty acids in phospholipids of red blood cell membranes and its connections to metabolic and nutritional status in healthy and diseased subjects. Full article
(This article belongs to the Special Issue Biomarkers in Blood 2016)
►▼ Show Figures

Figure 1

279 KiB  
Review
Fluid Biomarkers of Traumatic Brain Injury and Intended Context of Use
by Tanya Bogoslovsky, Jessica Gill, Andreas Jeromin, Cora Davis and Ramon Diaz-Arrastia
Diagnostics 2016, 6(4), 37; https://doi.org/10.3390/diagnostics6040037 - 18 Oct 2016
Cited by 68 | Viewed by 10600
Abstract
Traumatic brain injury (TBI) is one of the leading causes of death and disability around the world. The lack of validated biomarkers for TBI is a major impediment to developing effective therapies and improving clinical practice, as well as stimulating much work in [...] Read more.
Traumatic brain injury (TBI) is one of the leading causes of death and disability around the world. The lack of validated biomarkers for TBI is a major impediment to developing effective therapies and improving clinical practice, as well as stimulating much work in this area. In this review, we focus on different settings of TBI management where blood or cerebrospinal fluid (CSF) biomarkers could be utilized for predicting clinically-relevant consequences and guiding management decisions. Requirements that the biomarker must fulfill differ based on the intended context of use (CoU). Specifically, we focus on fluid biomarkers in order to: (1) identify patients who may require acute neuroimaging (cranial computerized tomography (CT) or magnetic resonance imaging (MRI); (2) select patients at risk for secondary brain injury processes; (3) aid in counseling patients about their symptoms at discharge; (4) identify patients at risk for developing postconcussive syndrome (PCS), posttraumatic epilepsy (PTE) or chronic traumatic encephalopathy (CTE); (5) predict outcomes with respect to poor or good recovery; (6) inform counseling as to return to work (RTW) or to play. Despite significant advances already made from biomarker-based studies of TBI, there is an immediate need for further large-scale studies focused on identifying and innovating sensitive and reliable TBI biomarkers. These studies should be designed with the intended CoU in mind. Full article
(This article belongs to the Special Issue Biomarkers in Blood 2016)
1903 KiB  
Review
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases
by Masayoshi Takeuchi
Diagnostics 2016, 6(2), 23; https://doi.org/10.3390/diagnostics6020023 - 7 Jun 2016
Cited by 44 | Viewed by 10843
Abstract
Advanced glycation end-products (AGEs) generated with aging or in the presence of diabetes mellitus, particularly AGEs derived from the glucose/fructose metabolism intermediate glyceraldehyde (Glycer-AGEs; termed toxic AGEs (TAGE)), were recently shown to be closely involved in the onset/progression of diabetic vascular complications via [...] Read more.
Advanced glycation end-products (AGEs) generated with aging or in the presence of diabetes mellitus, particularly AGEs derived from the glucose/fructose metabolism intermediate glyceraldehyde (Glycer-AGEs; termed toxic AGEs (TAGE)), were recently shown to be closely involved in the onset/progression of diabetic vascular complications via the receptor for AGEs (RAGE). TAGE also contribute to various diseases, such as cardiovascular disease; nonalcoholic steatohepatitis; cancer; Alzheimer’s disease, and; infertility. This suggests the necessity of minimizing the influence of the TAGE-RAGE axis in order to prevent the onset/progression of lifestyle-related diseases (LSRD) and establish therapeutic strategies. Changes in serum TAGE levels are closely associated with LSRD related to overeating, a lack of exercise, or excessive ingestion of sugars/dietary AGEs. We also showed that serum TAGE levels, but not those of hemoglobin A1c, glucose-derived AGEs, or Nε-(carboxymethyl)lysine, have potential as a biomarker for predicting the progression of atherosclerosis and future cardiovascular events. We herein introduce the usefulness of serum TAGE levels as a biomarker for the prevention/early diagnosis of LSRD and the evaluation of the efficacy of treatments; we discuss whether dietary AGE/sugar intake restrictions reduce the generation/accumulation of TAGE, thereby preventing the onset/progression of LSRD. Full article
(This article belongs to the Special Issue Biomarkers in Blood 2016)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop